About ResMed (ASX: RMD)
ResMed develops, manufactures, and markets medical devices and cloud-based software applications for the diagnosis, treatment, and management of respiratory disorders, serving customers across the United States and internationally. The company operates through two segments, Sleep and Breathing Health and Residential Care Software, addressing clinical and home-based care settings through an integrated combination of hardware and digital health tools.
On the device and monitoring side, ResMed offers diagnostic products such as ApneaLink Air, NightOwl, and EasyCare Tx for sleep apnea assessment, alongside cloud-based platforms including AirView for remote patient monitoring and myAir for personalized therapy management. Its software portfolio spans several brands serving post-acute and home-based care providers, with Brightree supporting home medical equipment and pharmacy organizations, HEALTHCAREfirst serving home health and hospice agencies, MatrixCare providing electronic health record solutions for skilled nursing and senior living communities, and MEDIFOX DAN catering to residential and home health providers in additional markets. Founded in 1989, ResMed is headquartered in San Diego, California.
MFAM Research
- [BUY] ResMed (ASX: RMD) – Growth Levers in Place for a Re-RateJune 23, 2026Buy ResMed at A$26.68 with a A$46.70 target and 75% upside. The GLP-1 fear is fading, new growth levers are scaling, and it trades below medtech peers.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARLatest Announcements
- ResMed Inc (ASX: RMD) – ResMed Files 2024 Annual ReportAugust 14, 2026ResMed announced a significant portfolio shift in its recently filed annual report. The company agreed to sell its MatrixCare business for $490 million in cash, marking a strategic narrowing toward sleep and breathing health solutions. The transaction announced June 30, 2026, is expected to close in the first quarter of fiscal 2027 and reflects management’s […]
- ResMed Inc (ASX: RMD) – ResMed Declares Dividend Distribution RMD 4August 7, 2026ResMed has declared a quarterly dividend of USD 0.066 per share for holders of Chess Depositary Instruments trading on the ASX. The announcement, made on 7 August 2026, represents the company’s Q3 2026 distribution and carries important implications for Australian investors holding the security. The ex-date of 19 August 2026 marks the final deadline for […]
- ResMed Inc (ASX: RMD) – ResMed Reports Q4 2026 ResultsAugust 7, 2026ResMed delivered strong results for fiscal year 2026, with full-year revenue reaching $5.7 billion, representing 10% growth or 8% growth on a constant currency basis. More notably for shareholders, the company’s non-GAAP diluted earnings per share increased 17% to $11.17, while the company returned more than $1 billion to shareholders through dividends and buybacks, a […]
- ResMed Inc (ASX: RMD) – ResMed to Sell MatrixCare Business UnitJuly 8, 2026ResMed has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in all-cash, marking a strategic pivot to return capital to shareholders while reshaping its portfolio. The transaction, expected to close in the first quarter of fiscal 2027 subject to regulatory approvals, signals ResMed’s intention to refocus […]
- ResMed Inc (ASX: RMD) – ResMed Announces Dividend Distribution PaymentMay 1, 2026ResMed Inc has declared an ordinary quarterly dividend of USD 0.06 per Chess Depositary Instrument, which equates to USD 0.60 per underlying NYSE share given the 10:1 CDI structure. The dividend relates to the company’s first quarter of 2026, ending 31 March, and will be payable on 18 June 2026 to shareholders on the record […]
- ResMed Inc (ASX: RMD) – ResMed Reports Q3 FY2026 ResultsMay 1, 2026ResMed delivered 11 percent revenue growth to $1.4 billion in the third quarter of fiscal 2026, alongside meaningful margin expansion that reflects improving operational leverage across the company’s global business. Gross margins expanded by 290 basis points on a non-GAAP basis to 62.8 percent, a substantial move that demonstrates ResMed’s ability to scale efficiently while […]
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Medical Instruments & Supplies |
|---|---|